Treatment options for patients with glioblastoma multiforme (GBM), the most common form of malignant gliomas, now include anti-angiogenic therapy after failure of standard multi-modality treatments.

Glioblastoma multiforme (GBM), commonly referred to as glioblastoma, is a malignant intracranial tumor derived from glial ...

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced ...

The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade ...

The study was published in Cancer Cell. Pediatric-type high-grade gliomas are currently incurable brain tumors with median survival times less than 18 months after initial diagnosis. Avapritinib is a ...

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis. Previous research suggests that platelet-derived growth ...

NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI) , a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare ...

Paediatric high-grade gliomas (pHGG) in particular are a mostly fatal disease group with a median survival time of less than 18 months after diagnosis and limited treatment options.

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis. Previous research suggests that platelet-derived ...

High-grade gliomas are very aggressive, with a prognosis of less than two years and limited treatment options. Though this work is preliminary, Koschmann is hopeful that avapritinib could be an ...

The University of Cincinnati Cancer Center and other research powerhouses have received a million-dollar grant.